Insights

Michael Camilleri, MD, from the Mayo Clinic, answers our questions about his research on fecal bile acids and fecal fat as potential biomarkers for irritable bowel syndrome, the importance of individualized treatment, and more.

Dr Ha, from Cedars-Sinai Medical Center, discusses the management of inflammatory bowel disease in the elderly, the potential for undertreatment, balancing medication interactions, and more.

In this video, Dr Aberra, from the University of Pennsylvania, discusses different types of infections that gastroenterologists should be aware of in inflammatory bowel disease (IBD), her own experience of treating a patient with IBD who...

Dr Hudesman, from NYU Langone Health, discusses when to withdraw medication among patients with inflammatory bowel disease, the risks associated with recurrence, if medication can be restarted, and more.

Adam Cheifetz, MD, from Beth Israel Deaconess Medical Center and Harvard Medical School, answers our questions about the expected increase in the number of available biosimilars for the management of IBD and the challenges gastroenterologists...

Brindusa Truta, MAS, MD, from Johns Hopkins Medicine, answers our questions about her study that evaluated pregnancy outcomes among mothers with IBD who discontinued therapy with infliximab early vs late during pregnancy.

Lindsey Albenberg, DO, from Children's Hospital of Philadelphia, discusses the role of the microbiome, as well as its influence on immunity and the development of pediatric inflammatory bowel disease.

In this video, Diane Mould, PhD, from Projections Research, discusses the important role of monoclonal antibodies in the management of inflammatory diseases.